BIOTECH CATALYST AI SCANNER — April WK2

Alex

03 Apr 2026 — 25 min read

The AACR Annual Meeting (April 17–22, Philadelphia) dominates the calendar this week. Six of the top 20 names are presenting oncology data at the same conference, creating a concentrated event window where strong individual results risk getting lost in the noise — and where a sector-wide rally or selloff can override any single catalyst. The XBI has been grinding sideways below its 200-day moving average against a macro backdrop of tariff uncertainty and muted risk appetite. Cash-strapped names are especially exposed in this environment.

This week also delivered one of those reminders the market sends periodically. LPCN's Phase 3 failure hit the stock like a freight train — a name that had been building momentum into its readout ended the week as a cautionary tale about just how brutal binary catalyst investing can be. When a Phase 3 misses, there is no partial credit. The setup doesn't matter. The prior data doesn't matter. The market doesn't grade on a curve.

A note before you read further: This scanner is a reference tool, not a recommendation engine — and that distinction matters more this week than usual. The BSI scores reflect setup quality based on technical positioning, balance sheet strength, and catalyst profile. They are not predictions of clinical outcomes, FDA decisions, or stock direction. Every name here is a starting point for your own due diligence, not a trade list. LPCN had supporters who felt the setup was compelling. That's not the same as doing the work. Do the work.

What We're Tracking:

Trading Below Cash: BCYC, ACRV, BIVI
Cash Pressure: GLSI, PSTV, COCP, BIVI, GNPX
Initial Data: AGEN, BIVI
Multi-Catalyst: ADAG (2 catalysts), ACRV (2 catalysts), KYTX (2 catalysts)

FEATURED — #1 through #10

#1. SRPT — Sarepta Therapeutics Inc.

THE CATALYST
Event: AMONDYS 45 (casimersen) + VYONDYS 53 (golodirsen) — NDA Filing Submission in Duchenne muscular dystrophy (DMD)
Date: Apr 2026 (Est.)
BSI: 7.9/10

Sarepta's PMO-based antisense oligonucleotides skip over the specific genetic defects in DMD — exon 45 and exon 53 respectively — enabling cells to produce a truncated but partially functional dystrophin. Unlike corticosteroids, which slow muscle breakdown without addressing the underlying mutation, these drugs attack DMD at the genetic level.

The Setup: The 76% decline from peak is the entry point conversation. Sarepta is not a pre-revenue company filing for the first time — it's an approved DMD franchise submitting sNDA applications to convert accelerated approvals to full approval, a pathway FDA built for exactly this transition. The ESSENCE trial and accumulating real-world evidence support that conversion. What the market is actually discounting is Elevidys franchise uncertainty, not Amondys/Vyondys specifically. A successful sNDA filing keeps the revenue base intact while the siRNA pipeline (in-progress with Arrowhead, using their TRiM platform) runs in parallel with almost no analyst attention.

Science & Edge: PMO exon-skipping restores the dystrophin reading frame disrupted by specific DMD mutations, enabling truncated dystrophin expression that partially preserves muscle function. The ESSENCE trial provides the clinical anchor for the sNDA conversion, supported by years of real-world safety and efficacy data. FDA's established sNDA pathway means the evidentiary bar is lower than for a new drug application, which is material to approval probability.

The Edge: Sarepta holds the only approved exon-45 and exon-53 skipping therapies in their respective mutation classes — no competitor has full approval in these subsets. Two-year cash runway means the company can execute on the sNDA filing without a financing overhang, and the Arrowhead siRNA partnership (FSHD1, DM1 programs via the TRiM platform) adds late-stage pipeline diversification that current valuation doesn't appear to credit.

The Risk: The 76% stock decline reflects lingering market skepticism about the Elevidys franchise — and FDA has shown willingness to reject DMD applications before, including earlier Sarepta programs. If sNDA review generates unexpected pushback on ESSENCE data adequacy or real-world evidence sufficiency, the thesis has limited near-term recovery catalysts. EPS estimates for FY2026 assume franchise recovery that hasn't materialized in the numbers yet.

#2. GLSI — Greenwich LifeSciences Inc.

THE CATALYST
Event: GP2 (GLSI-100) — Phase 3 Conference Presentation in HER2-positive breast cancer
Date: Apr 17, 2026
FDA Status: Fast Track Designation (FTD)
BSI: 7.9/10

GP2 is a peptide vaccine, not a monoclonal antibody — it trains HER2-specific CD8+ T-cells to recognize and eliminate cancer cells after standard treatment, aiming to prevent recurrence rather than treat active disease. That's a fundamentally different strategy from T-DM1 or trastuzumab, which require ongoing infusion to maintain benefit.

The Setup: The open-label non-HLA-A02 arm is already showing an 83% recurrence reduction versus Kadcyla's 4% annual recurrence control in the Katherine study. That's not incremental improvement. That's a different category of efficacy — if it holds in the blinded population. The problem is acute: negative cash and fewer than 60 days of runway make the April 17 AACR presentation a forcing function, not merely a data event. Positive data has to translate to financing almost immediately. A vaccine that outperforms Kadcyla by that margin would generate partnership interest quickly; the question is whether the blinded HLA-A02 arm confirms what the open-label arm suggests.

Science & Edge: GLSI-100 activates HER2-specific CD8+ T-cells via GP2 peptide plus GM-CSF adjuvant, generating delayed-type hypersensitivity immune responses. The open-label non-HLA-A*02 Phase 3 arm (250 patients) shows 0.7% annual recurrence post-PIS — an 83% reduction versus Kadcyla's 4% control (p<0.005). Five-year Phase IIb data showed 80%+ recurrence reduction in HER2 3+ patients. Unlike antibody-drug conjugates requiring ongoing IV infusion, a vaccine approach offers finite administration with lasting immunological memory.

The Edge: No other HER2 adjuvant vaccine has Phase 3 data. Kadcyla achieved its 40-50% RFS improvement through chronic ongoing dosing — GP2's one-time immunization model, if confirmed, represents a meaningfully different patient and payer proposition. If the blinded arm matches the open-label signal, Greenwich sits on data that AstraZeneca and Pfizer — who both know the adjuvant breast cancer space intimately — cannot currently match.

The Risk: The open-label numbers could reflect confounding in a non-randomized design. The blinded HLA-A*02 arm, covering the majority of the trial population, is the readout that actually matters, and it remains pending. Negative cash with imminent runway expiration means any financing event is dilutive at current prices, and a disappointing AACR presentation forces a distressed raise with no cover.

#3. IPHA — Innate Pharma S.A.

THE CATALYST
Event: IPH5201 (MATISSE) — Phase 2 in Neoadjuvant lung cancer
Date: Apr 17, 2026
BSI: 7.7/10

IPH5201 blocks CD39, an enzyme that degrades ATP into immunosuppressive adenosine within the tumor microenvironment. By removing that adenosine brake, IPH5201 attempts to restore immune activation in tumors that have learned to shut down the very T-cells trying to kill them — a mechanism PD-L1 inhibitors like durvalumab don't directly address.

The Setup: Roughly €42M in cash with a runway extending into Q3 2026 — Innate is working against a ticking clock. MATISSE is an interim analysis of 40 neoadjuvant NSCLC patients receiving IPH5201 on top of durvalumab and platinum-based chemotherapy. Durvalumab is already standard of care in some lung cancer settings, which means the April 21 AACR data needs to show additive benefit over a tough comparator — not just activity in monotherapy-naive patients. AstraZeneca's involvement provides development validation and institutional credibility, but Innate still needs to show the CD39 mechanism moves the needle in a population already receiving one of the most effective NSCLC regimens available. Positive data is almost a prerequisite for the non-dilutive financing the company is actively seeking.

Science & Edge: CD39 blockade removes an immunosuppressive substrate operating downstream of checkpoint inhibition — adenosine accumulation is a well-documented tumor escape mechanism that PD-1/PD-L1 inhibitors bypass entirely. MATISSE evaluates the triple combination in neoadjuvant NSCLC, where pathological complete response is the primary endpoint. Differentiated from standard durvalumab regimens by targeting tumor-specific immunosuppression rather than systemic T-cell activation.

The Edge: CD39 has one of the cleaner mechanistic rationales in immuno-oncology for combination with checkpoint blockade — the adenosine pathway and the PD-1 axis operate in parallel, not redundantly. AstraZeneca's durvalumab partnership provides both clinical infrastructure and implicit validation of the combination hypothesis from a company with deep NSCLC commercial experience.

The Risk: A 40-patient interim in a combination regimen at a neoadjuvant setting is too early to conclude anything definitively. The incremental benefit bar for adding a novel agent to an already-active durvalumab regimen is meaningful, and pathological complete response in a small exploratory cohort carries significant statistical uncertainty. A neutral or mixed signal here delays the story considerably without invalidating the mechanism.

#4. INKT — MiNK Therapeutics Inc.

THE CATALYST
Event: AGENT-797 — Phase 2 Interim Data in ARDS secondary to COVID-19
Date: May 11, 2026
BSI: 7.6/10

agenT-797 is an allogeneic off-the-shelf iNKT cell therapy — engineered from healthy donor cells and administered without patient-specific manufacturing. iNKT cells sit at the interface of innate and adaptive immunity, allowing simultaneous modulation of cytokine storms and activation of anti-tumor responses, a dual mechanism that checkpoint inhibitors and CAR-T therapies each lack.

The Setup: The May ASGCT abstract is the near-term hook, but the Phase 2 ARDS data in 2H 2026 is what the market will actually price. Phase 1/2 data published in Nature Communications showed >70% 30-day survival in mechanically ventilated severe ARDS patients — against roughly 10% historical controls in this population. That signal, if it holds in a randomized Phase 2, is not an incremental improvement; it's the kind of outcome that defines a new treatment category. Micro float of 5M shares means any institutional positioning ahead of the readout moves this name substantially, and the Agenus collaboration (botensilimab and balstilimab) extends the story into oncology as a second meaningful indication.

Science & Edge: Phase 1/2 ARDS data published in Nature Communications (February 2024) showed >70% 30-day survival in mechanically ventilated patients (80% in VV-ECMO subgroup) versus ~10% historical controls. In oncology, durable responses in PD-1-refractory gastric cancer. The allogeneic format eliminates the manufacturing delays inherent to autologous CAR-T, while the iNKT mechanism enables immune modulation in the highly inflammatory, dysregulated environment of critical illness.

The Edge: No approved therapy exists for severe ARDS with a survival signal approaching agenT-797's Phase 1/2 result. Unlike checkpoint inhibitors that require functional adaptive immunity to work, iNKT cells operate in the immunologically chaotic environment of critical illness — where most immunomodulators either fail or cause harm. The Agenus collaboration broadens the combination optionality into IO settings simultaneously.

The Risk: ARDS trials in mechanically ventilated ICU patients are operationally demanding and notoriously difficult to power. The randomized Phase 2 needs to replicate the Phase 1/2 survival signal under controlled conditions, in a patient population with high background mortality that can obscure treatment effects. Low volume (0.1x average) means the name can gap sharply in both directions on any clinical news with limited liquidity.

#5. PSTV — Plus Therapeutics Inc.

THE CATALYST
Event: CNSide (FORESEE) — Phase 1 Conference Presentation in Leptomeningeal Metastases from breast/NSCLC
Date: May 17, 2026
BSI: 7.6/10

CNSide is a quantitative CSF assay — not a drug — that counts tumor cells in cerebrospinal fluid to detect leptomeningeal metastases. At 80% sensitivity versus 29% for standard cytology, it doesn't narrow the gap with existing diagnostics: it makes the existing standard look obsolete in a disease where accurate detection directly changes treatment decisions.

The Setup: RSI of 96 on a stock that recently executed a 1:25 reverse split is a technical warning stacked on top of a structural capital problem. Going from 171M shares to 6.9M to meet Nasdaq minimum bid requirements signals distress — these are not voluntary optimization decisions. The IPSOR May presentation carries real diagnostic data (90%+ treatment decision influence against a 20% primary endpoint target), but near-term runway constraints mean the company needs to finance before the catalyst can deliver. The data is genuinely compelling; the capital structure makes positioning uncomfortable.

Science & Edge: CNSide employs proprietary tumor cell enumeration on CSF, achieving 80% sensitivity versus 29% for standard cytology in leptomeningeal metastasis detection, while influencing treatment decisions in over 90% of cases (primary endpoint: 20%). Standard cytology misses the majority of LM cases; CNSide's quantitative approach provides actionable information in a disease where imaging frequently fails to detect spread until it's advanced.

The Edge: No FDA-approved diagnostic exists specifically for leptomeningeal metastasis detection. CNSide is offered as a lab-developed test under CLIA/state lab licensing, with CPT/PLA coding in progress and payer coverage already in place (including Humana), giving it a practical commercial head start over any future competitor in this niche. The gap between 80% and 29% sensitivity is not a gap that gets closed incrementally — a competitor would need to build an entirely different technology to approach it.

The Risk: Our scoring flagged catalyst materiality as a concern — this is a conference poster presenting data that already exists, not a pivotal approval-path readout. The IPSOR presentation is further dissemination of previously announced results, which limits the new information content relative to the hype the stock has attracted. At RSI 96 with a recent reverse-split history, the technical setup argues for caution over momentum-chasing.

#6. ADAG — Adagene Inc.

THE CATALYST
Event: Muzastotug (ADG126) + KEYTRUDA — Phase 2 Conference Presentation in Solid tumors
Date: Apr 20, 2026
FDA Status: Fast Track Designation (FTD)
Additional catalysts: 1 more within 90 days
BSI: 7.5/10

Muzastotug is a "masked" anti-CTLA-4 antibody — it stays inert in normal tissue and activates only after tumor proteases cleave the masking domain inside the tumor microenvironment. Ipilimumab's toxicity problem is fundamentally about CTLA-4 inhibition happening everywhere in the body; muzastotug attacks that problem at the chemistry level rather than at the dose-management level.

The Setup: The AACR April 20 presentation brings Phase 1b/2 data: 31% confirmed ORR at 20 mg/kg, 6.7-month median PFS, and durable responses lasting beyond nine months — in MSS colorectal cancer, a historically immunotherapy-resistant setting where standard CTLA-4/PD-1 combinations achieve roughly 10% ORR. Volume spiked to 5x average ahead of this data — either informed positioning or momentum chasing into a binary event. Both interpretations warrant attention. A second AACR presentation on April 20 covers the ADG126 triple combination in hepatocellular carcinoma through the Morpheus Liver program, adding a second oncology readout at the same conference.

Science & Edge: Muzastotug's SAFEbody platform ensures CTLA-4 inhibition activates preferentially in the tumor microenvironment after protease cleavage, reducing immune-related toxicities that limit standard CTLA-4 agents. Phase 1b/2 data shows 31% confirmed ORR at 20 mg/kg versus 13% at 10 mg/kg — a clear dose-response relationship suggesting the mechanism is working. Durable responses beyond nine months in solid tumors resistant to standard immunotherapy represent a clinically meaningful advance over unmasked CTLA-4 agents.

The Edge: MSS colorectal cancer is an $8B+ addressable market where current immunotherapy regimens achieve ~10% ORR in unselected patients. A 31% ORR at the right dose, with median PFS above six months and a manageable safety profile, creates a data profile that could support accelerated development in a population that has no approved targeted IO option. The Fast Track designation provides FDA pathway support for that acceleration.

The Risk: China-based operations expose Adagene to HFCAA delisting risk and data export regulations — an unpredictable regulatory overlay beyond FDA that a pure US or EU company doesn't face. Even compelling Phase 2 data can face execution friction in partnership discussions when the originating company has operational complexity in China. The 5x volume spike ahead of data warrants careful scrutiny of whether current pricing reflects the actual content of the AACR presentation.

#7. GRCE — Grace Therapeutics Inc.

THE CATALYST
Event: GTX-104 (STRIVE-ON) — PDUFA Regulatory Decision in Aneurysmal Subarachnoid Hemorrhage
Date: Apr 23, 2026
FDA Status: Orphan Drug Designation (ODD)
BSI: 7.5/10

GTX-104 reformulates nimodipine — a calcium channel blocker used in subarachnoid hemorrhage for forty years — into an IV nanoparticle formulation that enables peripheral infusion. The drug itself is not new; the delivery solves a real clinical problem. In the ICU, oral nimodipine requires nasogastric tube administration in unconscious or intubated patients, with variable absorption and hypotension risk. GTX-104 eliminates those problems.

The Setup: Three weeks to PDUFA, stock up 36% over 21 days, RSI at 74 — this is the classic momentum-into-binary setup. Grace has the wind at its back: NDA accepted, Phase 3 STRIVE-ON met its primary hypotension endpoint, and orphan drug status provides seven-year exclusivity if approved. The competitive angle is unusual — oral nimodipine is cheap, unpatented, and entrenched, but nobody has challenged it with an IV reformulation that works in the ICU setting until now. Grace holds 40+ patents protecting GTX-104 with no direct IV competitor on the market, meaning approval creates a near-monopoly in a rare indication that no generic can immediately enter.

Science & Edge: STRIVE-ON (n=102) showed GTX-104's superiority on the primary endpoint: a 19% relative reduction in clinically significant hypotension (28% vs. 35%) with fewer ICU days and ventilator time versus oral nimodipine. The nanoparticle formulation achieves stable IV delivery with controlled pharmacokinetics, eliminating the nasogastric tube requirement and absorption variability that make oral nimodipine difficult to use in critically ill aSAH patients.

The Edge: Nimodipine has been the only approved vasospasm prevention option in aSAH for four decades — an off-patent generic with a known administration problem that no one has solved at FDA level before GTX-104. Orphan designation, 40+ patents, and Phase 3 data together create a durable commercial moat in a clinical setting where intensivists have been working around oral nimodipine's limitations for years.

The Risk: The trial was small at n=102, and the primary endpoint is a safety measure — a reduction in hypotension events — rather than a traditional efficacy outcome showing reduced vasospasm or improved neurological outcomes. If FDA views the primary endpoint as insufficient evidence of clinical benefit superior to oral nimodipine, the approval argument weakens significantly. At $69M entering a binary PDUFA, the downside on rejection is not symmetric.

#8. BCYC — Bicycle Therapeutics plc

THE CATALYST
Event: BT5528 + OPDIVO — Phase 1/2 Conference Presentation in Solid tumors
Date: Apr 19, 2026
BSI: 7.4/10

Bicycle Therapeutics builds small synthetic peptide-toxin conjugates that bind cancer targets with antibody-like affinity while penetrating solid tumor interiors that conventional antibodies physically cannot reach. BT5528 targets EphA2 — a receptor overexpressed across multiple solid tumors — delivering cytotoxic payload combined with Opdivo to activate checkpoint-mediated immune clearance simultaneously.

The Setup: The pipeline is priced at below zero — cash exceeds market cap by a substantial margin, a valuation the market typically reaches when it has lost patience with a story. Bicycle took hits when earlier programs ran into setbacks, but BT5528's ESMO 2024 data changed the narrative: 43% ORR in EphA2-positive patients (6/14) versus 20% in EphA2-negative (2/10). That biomarker correlation is exactly the pattern you look for in early phase dose-escalation data. AACR April 19 brings both preclinical work and expanded Phase 1/2 data — the question is whether the ESMO signal holds under broader scrutiny or was noise in a small cohort. The BT8009 nectin-4 program runs in parallel, with an End of Phase meeting coming that will set pivotal design parameters.

Science & Edge: BT5528's Bicycle peptide scaffold penetrates solid tumor interiors better than antibody-drug conjugates like Padcev (enfortumab vedotin), delivering cytotoxic payload to cancer cells that larger molecules can't access. ESMO Phase 1/2 data: 43% ORR in EphA2-positive patients versus 20% in EphA2-negative — a differential that validates the biomarker hypothesis. The small molecule size enables tumor penetration in dense, poorly vascularized solid tumors where ADCs lose efficacy.

The Edge: A market pricing the pipeline at negative means any positive signal generates convex upside — not because the data is incremental but because the baseline expectation is approximately zero. Cash substantially covers the current enterprise value, providing over 21 months of runway into what should be a data-rich 1H 2026. The BT8009 nectin-4 program adds a parallel catalyst in a space where Padcev has already validated the commercial target.

The Risk: Phase 1/2 data in 14 EphA2-positive patients is statistically fragile — the AACR presentation needs to expand the dataset and ideally confirm responses rather than add more unconfirmed data points. The BT8009 End of Phase FDA meeting sets the pivotal trial requirements; demanding endpoint or design demands could push the most advanced asset considerably further into the future than current setup implies.

#9. NUVB — Nuvation Bio Inc. Class A

THE CATALYST
Event: Taletrectinib (TRUST-I) — Phase 2 Conference Presentation in ROS1-positive NSCLC
Date: Apr 21, 2026
FDA Status: Breakthrough Therapy Designation (BTD), Orphan Drug Designation (ODD)
BSI: 7.4/10

Taletrectinib inhibits ROS1 fusion proteins — oncogenic drivers in roughly 2% of NSCLC cases — with substantially better brain penetration and durability than first-generation crizotinib. In a patient population where brain metastases are common and crizotinib resistance emerges predictably, both properties translate directly into survival outcomes.

The Setup: FDA approved taletrectinib in June 2025 — this is a commercial-stage asset, not a development bet. The AACR April 21 presentation updates TRUST-I China data, reinforcing an already-approved US indication. Breakthrough designation is in place, EMA filing is underway through Eisai, and Japan approval is already secured. With over four years of cash runway, Nuvation can sustain global rollout without a financing overhang. The conversation now is commercial ceiling: ROS1+ NSCLC is only ~2% of cases, and lorlatinib (primarily an ALK inhibitor with limited ROS1 data) provides peripheral competition. For a newly approved oncology drug with global regulatory momentum, current valuation doesn't appear to price in much success outside the US.

Science & Edge: TRUST-I/II data: 89% ORR in TKI-naive and 56% in TKI-pretreated ROS1+ NSCLC. Updated median duration of response reached ~44 months in TKI-naive patients — a figure that makes crizotinib's ~19-month DOR look like a first-generation benchmark. Intracranial efficacy is critical: brain metastases affect roughly 40% of advanced ROS1+ patients, and crizotinib's poor CNS penetration is one of the main reasons patients eventually progress.

The Edge: Already approved with real-world rollout beginning. The ~44-month median DOR in TKI-naive patients is the clinical anchor — no approved ROS1 TKI matches it, and the data package supporting US approval is now reinforcing a global regulatory expansion through partners with established NSCLC commercial infrastructure in Japan and Europe.

The Risk: Commercial ceiling in a 2% NSCLC subpopulation is real. Global expansion through Eisai creates partnership dependency on a company with its own commercial priorities that may not fully align with NUVB's. TRUST-III confirmatory trial in China runs to primary completion in 2030, extending the confirmatory data story well beyond most investors' typical horizon.

#10. AGEN — Agenus Inc.

THE CATALYST
Event: Botensilimab (BOT) + Balstilimab (BAL) — Phase 2 Conference Presentation (Initial Data) in 1L MSS mCRC without liver/bone/brain metastasis
Date: Apr 21, 2026
BSI: 7.2/10

Botensilimab is an Fc-enhanced anti-CTLA-4 antibody — the Fc engineering activates innate immune cells (myeloid cells, NK cells) in addition to the adaptive T-cell responses that unmodified ipilimumab generates. In "cold" tumors like MSS colorectal cancer, where adaptive immunity is largely shut out, that additional innate arm may be what's needed to create the immune response at all.

The Setup: MSS colorectal cancer is one of the last immune-excluded tumor types without an approved immunotherapy option. Agenus is presenting Phase 2 preliminary data from a trial that specifically enrolls patients without liver, bone, or brain metastases — a population where the tumor immune microenvironment is less suppressed than in heavily metastatic disease. The BOT+BAL combination has shown activity in late-line MSS mCRC; this 1L study in a more favorable subgroup is first-in-kind. Regeneron's cemiplimab is also developing in colorectal, and the broader CTLA-4 combination landscape is crowded — Agenus needs differentiated data to define its position.

Science & Edge: BOT's Fc enhancement primes T-cells, depletes regulatory T-cells, and activates myeloid cells for memory responses in tumors that exclude standard immunotherapy. Balstilimab sustains PD-1 blockade. The trial design — excluding patients with liver/bone/brain mets — enriches for the subgroup where the immune microenvironment is most amenable to this dual activation approach. Approximately 1,200 patients treated to date across programs; this is the first Phase 2 in 1L MSS CRC with this immune subgroup restriction.

The Edge: First Phase 2 data in 1L MSS mCRC designed for chemo-free immunotherapy in a favorable metastatic subgroup. No competitor has presented data in this exact population design. If BOT+BAL generates ORRs meaningfully above the 5-10% seen with single-agent checkpoint inhibitors in unselected MSS CRC, the case for Fc-enhanced CTLA-4 in cold tumors gains substantial clinical credibility.

The Risk: Investigator-sponsored preliminary cohort — first human data in this specific population and design. An uncertain or inconsistent signal won't generate the Phase 3 acceleration the thesis requires. The runway to clinical and commercial value is not generous, and dilution before the thesis resolves is a real scenario that current investors need to weigh.

WATCHLIST — #11 through #20

#11. ACRV — Acrivon Therapeutics Inc. [Oncology]

Price: $1.52 | Cap: $59M | Cash: $103M | RSI: 44.0 | Momentum: -5.0%
ACR-368 — Phase 2b Conference Presentation in Platinum-resistant ovarian/endometrial/urothelial cancers (Apr 20, 2026)
ACR-2316 — Phase 1 Presentation in Solid tumors (Apr 20, 2026)
FDA Status: BTD, FTD
BSI: 7.3/10

The Intel: Negative enterprise value situation: $103M cash against a $59M market cap means Acrivon's CHK1/2 inhibitor program trades at below zero. Phase 2b showed 67% confirmed ORR in biomarker-positive serous ovarian cancer patients with ≤2 prior lines of therapy — a number that, if sustained in expanded enrollment, would put ACR-368 ahead of approved PARP inhibitors in this patient subgroup. The AP3 proteomics platform that identifies drug-sensitive tumors is the differentiated element, trading against Verastem and standard PARP inhibitors (olaparib, niraparib) that lack patient-selection biomarkers with this precision. Two AACR presentations on April 20, adding a Phase 1 ACR-2316 (dual WEE1/PKMYT1 inhibitor) readout alongside the Phase 2b update.

#12. OCUL — Ocular Therapeutix Inc. [Ophthalmology]

Price: $8.49 | Cap: $1.85B | Cash: $681M | RSI: 45.9 | Momentum: -17.8%
AXPAXLI (OTX-TKI, SOL-1) — Phase 3 Conference Presentation in Wet AMD (Apr 11, 2026)
BSI: 7.2/10

The Intel: AXPAXLI is a sustained-release intravitreal axitinib formulation targeting quarterly or annual dosing — versus the monthly injection burden that defines Eylea and Lucentis for wet AMD. Phase 3 SOL-1 showed statistical superiority over aflibercept: 74.1% of patients maintaining vision at Week 36 (17.5% risk difference) and 65.9% at Week 52 (21.1% risk difference). The April 11 VBS presentation and April 15 CNO presentation add detail to topline data already released, with an NDA filing as the next gating milestone. At $681M cash and 37-month runway, OCUL has the financial position to support the NDA process without dilution. Regeneron's Eylea HD (extended dosing) is the primary commercial comparison — the durability question is whether AXPAXLI's dosing flexibility advantage justifies the switch in a market where Eylea has deep prescriber relationships.

#13. ALLO — Allogene Therapeutics Inc. [Hematology/Oncology]

Price: $2.48 | Cap: $605M | Cash: $222M | RSI: 52.0 | Momentum: +7.4%
Cema-cel (ALPHA3) — Phase 2 Interim Data in Large B-Cell Lymphoma (Apr 2026, Est.)
BSI: 7.1/10

The Intel: Allogene is the best-capitalized pure-play in allogeneic CAR-T — 24 months of runway, a pivotal trial underway, BLA filing on the roadmap. ALPHA3 tests cema-cel as first-line consolidation in LBCL patients with minimal residual disease after standard induction — a disease-earlier strategy targeting a population with better immune function than the heavily pre-treated patients where autologous CAR-T (Yescarta, Breyanzi) competes. April interim data will show whether MRD-directed consolidation generates durable complete responses, the gating question for BLA timing. The allogeneic format versus autologous gives Allogene a manufacturing advantage — if the clinical data holds, the commercial story around off-the-shelf availability is meaningful.

#14. COCP — Cocrystal Pharma Inc. [Infectious Disease]

Price: $1.51 | Cap: $21M | Cash: $5.2M | RSI: 77.3 | Momentum: +51.0%
CDI-988 — Phase 1b Conference Presentation in Norovirus (Apr 27, 2026)
FDA Status: Fast Track Designation (FTD)
BSI: 7.0/10

The Intel: No approved antiviral exists for norovirus — an indication affecting 600 million people annually and representing a major liability in hospital outbreaks, nursing homes, and cruise ships. CDI-988 inhibits the 3CL protease conserved across all norovirus genotypes, meaning it could work regardless of which strain triggers an outbreak. The Emory University Phase 1b challenge study began dosing in March 2026, with data at ICAR April 27–May 1. Cash crunch is real at $5.2M with under 9 months of runway. RSI is 77, momentum is +51% — this name has moved substantially ahead of the data, and any result short of a clean safety and early efficacy signal will be an uncomfortable exit. Position sizing should reflect that.

#15. KYTX — Kyverna Therapeutics Inc. [Autoimmune]

Price: $8.87 | Cap: $536M | Cash: $245M | RSI: 48.9 | Momentum: +5.7%
Miv-cel (KYV-101, KYSA-6) — Phase 2 Interim Data in Myasthenia Gravis (Apr 20, 2026)
Miv-cel (KYV-101, KYSA-8) — Phase 2 Data in Stiff-Person Syndrome (Apr 21, 2026)
FDA Status: FTD, ODD, RMAT Designation
BSI: 6.9/10

The Intel: Kyverna is presenting at AAN on back-to-back days across two distinct autoimmune indications — an unusual data concentration for a single asset. In myasthenia gravis, prior AANEM data showed 100% of patients hit both MG-ADL and QMG co-primary endpoints at 24 weeks, the same endpoints designed for the Phase 3 trial. In stiff-person syndrome, Phase 2 met all primary and secondary endpoints. RMAT designation signals FDA sees potential for a CAR-T immune reset approach to autoimmune disease as transformative. Two BLA submissions are now on the near-term roadmap, and the AAN double-header will clarify durability data that Phase 3 pivotal enrollment will depend on.

#16. BIVI — BioVie Inc. [Neurology]

Price: $1.42 | Cap: $11M | Cash: $16M | RSI: 50.7 | Momentum: +6.0%
Bezisterim (NE3107, SUNRISE-PD) — Phase 2 Conference Presentation (Initial Data) in Parkinson's disease (May 17, 2026)
BSI: 6.8/10

The Intel: Cash exceeds market cap — BioVie trades below its cash balance, making the setup a question of whether the pipeline has any value at all. Bezisterim targets neuroinflammation and insulin resistance in Parkinson's, two mechanisms almost entirely absent from the dopamine-focused therapeutic landscape (levodopa, dopamine agonists). SUNRISE-PD topline results are expected mid-2026, with an abstract at conference in May serving as a preview. The Phase 2a met primary endpoints in 2022 with significant improvements in non-motor symptoms; the Phase 2 full trial result is the actual proof point. Runway of ~11 months against a Phase 2 readout creates urgency around bridge financing.

#17. WVE — Wave Life Sciences Ltd. [Respiratory]

Price: $7.28 | Cap: $1.37B | Cash: $567M | RSI: 23.0 | Momentum: -44.8%
WVE-006 (RestorAATion-2) — Phase 1/2 Interim Data in Alpha-1 Antitrypsin Deficiency (May 18, 2026)
BSI: 6.8/10

The Intel: RSI of 23 and -45% momentum on a company with over four years of cash runway is the kind of dislocation that either resolves on a catalyst or grinds sideways for another two years. WVE-006 is the industry's first RNA editing therapy for AATD — it corrects the mutant SERPINA1 mRNA base directly (A to I editing) rather than silencing or supplementing, a mechanism that Vertex and AstraZeneca's liver-targeted approaches don't replicate. The ATS May 18 presentation will show 400 mg and 600 mg cohort data from RestorAATion-2, with the key question being whether higher doses generate the AAT protein normalization needed for disease modification. A positive update was announced in September 2025; May will show whether the dose-response continues to hold.

#18. MIRA — MIRA Pharmaceuticals Inc. [Neurology]

Price: $1.11 | Cap: $47M | Cash: $9.8M | RSI: 44.8 | Momentum: -5.9%
Ketamir-2 — Phase 1 Conference Presentation in Neuropathic pain (Apr 17, 2026)
BSI: 6.8/10

The Intel: Phase 1 dosing for Ketamir-2 wrapped in March 2026, and AACR April 17–22 will present the safety and tolerability data. The drug showed a clean safety profile at all dose levels — necessary but not sufficient — in an indication where spinal cord stimulators, duloxetine, and gabapentinoids are deeply entrenched. Note: our scoring flagged catalyst materiality as a concern here. This is a Phase 1 tolerability conference presentation, not a pivotal efficacy readout. Phase 2a is the actual signal-generating trial, and it hasn't started yet. Strong 24-month runway gives MIRA time to get there without dilution pressure, but current catalyst visibility is limited, and the neuropathic pain commercial landscape is challenging even with strong Phase 2 data.

#19. OKYO — OKYO Pharma Limited [Ophthalmology]

Price: $1.68 | Cap: $57M | Cash: $6.3M | RSI: 51.8 | Momentum: -0.6%
Urcosimod (OK-101) — Phase 2a Conference Presentation in Neuropathic Corneal Pain (Apr 11, 2026)
FDA Status: Fast Track Designation (FTD)
BSI: 6.8/10

The Intel: Urcosimod targets ChemR23, a GPCR receptor that modulates corneal inflammation and neuropathic pain — a mechanism distinct from steroids, cyclosporine, or the anti-VEGF approaches common in ophthalmology. OKYO holds the first FDA IND clearance for a neuropathic corneal pain trial, with no approved competitor in this indication. Phase 2a data at ASCRS April 11 showed clinically meaningful improvement in quality-of-life metrics (mean -4.5 change from baseline in enjoyment of life/relationships versus 0 for placebo). Cash is thin at $6.3M with no clear runway buffer, and a second ARVO presentation (May 3–7) will provide a more complete Phase 2a dataset. ARVO is the more data-complete of the two near-term events.

#20. GNPX — Genprex Inc. [Oncology]

Price: $1.54 | Cap: $14M | Cash: $3.6M | RSI: 21.7 | Momentum: -23.0%
REQORSA + TAGRISSO (Acclaim-1) — Phase 1/2 Interim Data in NSCLC (Apr 19, 2026)
FDA Status: Fast Track Designation (FTD)
BSI: 6.7/10

The Intel: RSI of 22, -23% momentum, and $3.6M cash with a 2.6-month runway — GNPX is on the edge of insolvency. The AACRO April 19 presentation covers Acclaim-1 Phase 2a data combining REQORSA (a non-viral gene therapy delivering tumor suppressor genes via the Oncoprex system) with AstraZeneca's osimertinib in EGFR-mutated NSCLC. The rationale: restore suppressed tumor suppressor pathways to overcome acquired osimertinib resistance, a clinically significant problem in a setting where Tagrisso is a multi-billion dollar standard of care. Positive combination data would be scientifically meaningful. But with sub-3-month runway, the question of whether the company exists post-presentation is not rhetorical. Fast Track designation provides some FDA pathway clarity; financing does not resolve itself from data alone at this scale.

The Strategist's Take

This week's scanner is an AACR-heavy list landing at a moment when the sector needs to prove something. Six featured names present at the same conference over five days — meaning investor attention will fragment across presentations, and the names without clean binary structures will struggle to generate sustained price action even on good data. In that environment, the cleanest setup in the featured list is GRCE: a PDUFA on April 23 with Phase 3 data already in hand, orphan drug exclusivity waiting on the other side, and no IV competitor in a niche that's been medically underserved for four decades. A $69M market cap on a yes/no FDA decision with a defensible clinical package is the kind of setup that doesn't need an AACR backdrop to work.

GLSI is the week's highest-stakes catalyst. The open-label HER2 vaccine data is genuinely extraordinary if the blinded arm confirms it — an 83% recurrence reduction would rewrite the adjuvant breast cancer treatment paradigm in a space Kadcyla currently defines. But we just watched LPCN turn compelling expectations into a cautionary tale in a single session. GLSI has the added complexity of negative cash, meaning the data event and the financing event need to happen in essentially the same window. That's not impossible, but it requires everything to go right simultaneously.

Among the negative-EV situations, BCYC stands out for the cleanest setup quality: the ESMO EphA2 biomarker correlation was the right kind of early Phase 1/2 signal (positive in biomarker-positive, less so in biomarker-negative), and AACR April 19 expands that dataset. With cash covering more than the entire market cap and over 21 months of runway, Bicycle can absorb a mixed readout without existential consequences — a luxury that GNPX (2.6-month runway) and GLSI (negative cash) demonstrably do not have. Our scoring flagged PSTV and MIRA on catalyst materiality — both are presenting data that has already been announced, and readers should approach those names knowing the information-value of the upcoming presentations is limited relative to the hype surrounding them.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.